In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. by unknown
In vivo cholesterol kinetics in apolipoprotein 
E-deficient and control mice 
S. H. Quarfordt,”* B. Oswald,’ B. Landis,* H. S. Xu,’* S. H. Zhang,t and N. Maedat 
Department of Medicine,’ Durham VA Hospital and Duke University Medical Center, Durham, NC 
27705; Department of Pathology,t University of North Carolina, Chapel Hill, NC 27599; and Department 
of Surgery,’* University of Virginia, Charlottesville, VA 22908 
Abstract The in vivo total body cholesterol transport of 
homozygous apoE-deficient (-/-) and control (+/+) mice was 
evaluated by compartmental analysis of plasma cholesterol de- 
cay. Body cholesterol fractional catabolic rates of chow fed mu- 
tants were less (-/-, 0.17 * 0.02; +/+, 0.51 * 0.06 day-’) and body 
cholesterol contents greater (-/-, 68 * 5; +/+, 48 * 5 pmol) 
than controls. The body cholesterol expansion of the chow-fed 
mutant was extracellular with at least half in plasma. Cholesterol 
transport, Le., the mass entering, moving through, and exiting 
the body eachday, was similar (-/-, 6.9 * 0.7; +/+, 8.5 * 0.9 
pmollday) for homozygotes and controls on chow, and both tri- 
pled with cholesterol feeding. Differing from controls, however, 
mutants had considerable expansions of plasma and body 
cholesterol (-/-, 166 * 21; +/+,  59 + 11 pmol) with incre- 
ments in peripheral tissue cholesterol contents. Cholesterol feed- 
ing increased control hepatic cholesterol without a change in 
plasma, whereas mutants had large increments in plasma 
cholesterol with no change in liver. Consistent with impaired 
hepatic uptake of cholesterol, mutants had much slower plasma 
clearance of lipoprotein cholesterol, as well as slower transfer to 
catabolic pools than normals. Treatment of homozygotes with 
lovastatin doubled both plasma cholesterol concentration and 
body cholesterol transport indicating the importance of apoE- 
dependent cell cholesterol transfer in synthetic down-regulation 
with this agent. M These data indicate that mice lacking apoE 
have lower affinity hepatic uptake of plasma remnant 
cholesterol. This is an important factor in producing a lower to- 
tal body cholesterol fractional catabolic rate which results in a 
considerable increase in body cholesterol mass to achieve trans- 
port capacities equivalent to mice with apoE.-Quarfordt, 
S.  H., B. Oswald, B. Landis, H. S.  Xu, S.  H. Zhang, and N. 
Maeda. In vivo cholesterol kinetics in apolipoprotein E-deficient 
and control mice. J.  Lipid Res. 1995. 36: 1227-1235. 
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The absence of apoE changes the access of plasma 
lipoprotein cholesterol to cells in mice with this deletion. 
Rather than the characterized (1) remnant receptor, possi- 
bly low density lipoprotein related protein (2) and ap- 
propriate proteoglycans (3) that bind apoE, chylomicron 
and very low density lipoprotein (VLDL) remnant 
cholesterol enter hepatocytes by an apoE-independent 
system. The small amount of mouse apoB-100 on low den- 
sity lipoproteins (LDL) and VLDL (4), and the greater 
affinities of apoE for the LDL receptor (5), would also 
limit cell cholesterol uptake by this receptor. 
The mutants lacking apoE move cholesterol from 
plasma into cells by uncharacterized pathways obviously 
independent of apoE. At present, we have little under- 
standing of the properties of such pathways other than the 
observation that remnant-like lipoproteins accumulate in 
the mutant plasma even on standard chow diets (6 ,  7). 
This suggests that apoE-independent clearance has lower 
affinity and possibly even lower capacity than that depen- 
dent on apoE. Other properties of apoE-independent 
plasma lipoprotein cholesterol transport, including molecu- 
lar mechanisms, are undefined. 
Aside from altering plasma lipoprotein cholesterol 
transport, the lack of apoE quite likely influences total 
body cholesterol homeostasis. Any impairment in provid- 
ing plasma cholesterol to cells, particularly hepatocytes 
(8), could up-regulate synthesis and increase total body 
transport of cholesterol. Such an occurrence could exacer- 
bate the plasma hypercholesterolemia and, depending on 
catabolism, increase whole body cholesterol mass. Se- 
condly, apoE-independent transport may result in a cata- 
bolic defect manifested by a lower body cholesterol frac- 
tional catabolic rate and a larger whole body cholesterol 
mass than controls. As remnant transport has been pro- 
posed (9) as a major vehicle for reverse cholesterol trans- 
port, any limitation in this pathway may influence 
catabolism. Finally, although the mutants have major 
increments in plasma cholesterol, this may simply reflect 
an altered distribution of body cholesterol. Total body 
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cholesterol mass, the transport of cholesterol through the 
body, and body cholesterol fractional catabolic rate may 
be the same for mutant and control. 
The studies presented here determine parameters of in 
vivo cholesterol transport in homozygous apoE-deficient 
mice and their control littermates. The studies were done 
on mice fed standard chow where synthesis was the 
predominant input. Other studies evaluated effects of 
lovastatin-induced alterations in synthesis in control and 
mutant mice. Finally, cholesterol transport was enhanced 
in both types of mice by cholesterol feeding. 
MATERIALS AND METHODS 
Materials 
[1,2-3H]cholesterol and [23-14C]taurocholate were pur- 
chased from DuPont New England Nuclear (Boston, 
MA). [4-14C]cholesterol came from Amersham (Chicago, 
IL). Egg phosphatidylcholine was from Avanti (Pel, AL) 
and cholesterol from Alltech (Deerpark, IL). The tracer 
and cold cholesterol were determined to be pure (> 99%) 
by both adsorptive and reverse-phase thin-layer chro- 
matographic systems. Organic solvents were obtained 
from Mallinckrodt (St. Louis, MO) and were analytic 
grade. Lard was obtained from Fischer (Louisville, KY) 
and dietary cholesterol from ICN (Aurora, OH). Lovasta- 
tin was a generous gift from Merck, Sharpe and Dohme 
(Rahway, NJ). 
Animals 
Control mice were normal littermates of the mutant 
mice with apoE deletions (10). Males and females ranging 
in weight from 15 to 36 g and in age from 2 to 10 months 
were used. On a standard rodent chow diet the mice with 
homozygote deletions had body weights similar to those of 
control mice and all had plasma cholesterol levels at least 
fourfold the control. All mice were maintained on either 
standard rodent chow 3000 (Agway; Syracuse, NY con- 
taining 0.01 % cholesterol by gas-liquid chromatography) 
or chow supplemented with 10% lard and made to 1% 
cholesterol, or chow containing 0.025% lovastatin. They 
were fed for at least 3 weeks prior to study. Isotopic 
studies were initiated between 8 and 10 AM. Tracers were 
injected in the tail vein and blood was obtained from the 
retroorbital plexus. 
Cannulation of the bile duct in both control and mu- 
tant mice was achieved with Tygon tubing (0.25 mm ID, 
0.75 mm OD) (Norton Co., Akron, OH) at the level of the 
mid common duct after 1 mg intraperitoneal pentobarbi- 
tal anesthesia. A cannula was also placed in the mid 
duodenum. Both cannulas were tunneled to the dorsal 
cervical area where they were connected with PE 60 tub- 
ing (Becton Dickinson, Parsippany, NJ) to maintain an 
intact enterohepatic circulation, an important deter- 
minant (11) of the precursor source of biliary cholesterol 
and bile acid. The day after surgery the bile flows of the 
mice were measured and those less than 50 pl/h were ex- 
cluded from study. The remaining mice were injected 
with apoE-deficient homozygote serum containing 0.1 
FCi, 1.4 pmol [1,2-3H]cholesterol-labeled lipoproteins that 
had been harvested from mutants injected with free 
cholesterol in phosphatidylcholine the previous day and 
determined to have more than 65% of the tracer in 
cholesteryl ester. Serum was obtained at intervals and, af- 
ter ultracentrifugation, was assayed for tracer distribution 
in both the d 1.063 g/ml top and bottom and in free and 
esterified cholesterol. Bile was collected for 2-h intervals 
during the day and two-thirds of the bile was returned to 
the duodenum. The cannulas were connected throughout 
the night and reopened the following morning and similar 
aliquots were obtained. At the conclusion of the study 
[23-’4C]taurocholate (0.1 pCi) was put in the intestine 
and bile samples were obtained 4-8 h later to determine 
pool size by an isotope dilution method (12). 
To evaluate in vivo cholesterol kinetics, tracer (3-6 pCi) 
free cholesterol (10 pg) was injected as a 4/1 molar ratio 
of egg phosphatidylcholinelfree cholesterol in 0.5 ml of 
phosphate (0.2 M,  pH 7.4)-buffered saline (0.13 M). All 
injections were in the tail vein and blood was obtained 
from the retroorbital plexus. Early (5-120 min) blood 
sampling of both controls and homozygotes established 
that 30 min was required for the initial exponential of de- 
cay to appear. The first blood sample (50 pl )  was obtained 
at that time, then daily for 4 days, and biweekly out to 3 
or 4 weeks. At the conclusion of the study, the mice were 
exsanguinated and the tissues were extracted and assayed. 
Analytic methods 
Free and esterified cholesterol was extracted from 
plasma and tissue by the Dole method (13). Determina- 
tions of cholesterol mass were by a cholesterol oxidase 
method using commercial kits for both free and esterified 
cholesterol (Wako, Osaka, Japan). The mouse plasma was 
made to d 1.063 g/ml and ultracentrifuged (1.8 x lo8 g 
min) in a Beckman Model L5-75 centrifuge (Palo Alto, 
CA) to separate lower and higher density lipoproteins 
(14). Tracer free and esterified cholesterol were isolated by 
thin-layer chromatography on silica gel G with the solvent 
system petroleum ether-diethyl ether-glacial acetic acid 
80:20:1. Biliary cholesterol was separated from the bile 
acids by a chloroform-methanol 2:l (20 vol/vol bile) ex- 
traction. After the phases were split with 5 vols 0.05% 
H2S04, the chloroform phase was taken for cholesterol 
mass and radioactivity assay, and the methanol phase for 
similar assays of bile acids. Bile acid mass was determined 
by a 3a-steroid dehydrogenase method (15). Bile acids 
were radioassayed in an aqueous scintillation cocktail 
3a70B (Research Products, Mt. Prospect, IL) and 
cholesterol in 0.5% 2,5 diphenyloxazole, 0.01 % phenylox- 
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Fig. 1. Plasma cholesterol decay in chow-fed normal and homozygote 
apoE-deficient mice. The data are representative plasma cholesterol 
specific activity functions from normals (+/+, top panel) and 
homozygotes (-I-, bottom panel) after the injection of [1,2-SH]cholesterol. 
The curves are the simulations using the two-pool model from the ex- 
perimental data points presented. 
azolylbenzene in toluene. Radioassay was in a Beckman 
(Palo Alto, CA) model 8100 liquid scintillation spec- 
trophotometer. 
Calculations 
All isotopic data were expressed as the fraction of in- 
jected activity per pmol of cholesterol. The biexponential 
plasma decay data were simulated by a two-compartment 
model previously used (16) in the analysis of similar hu- 
man data using the program SAAM 31 (17). Pool 1, or the 
pool into which the isotope was introduced, was termed 
the rapid pool (R) and the second pool was termed the 
slow pool (S). These two pool models assume all input 
into and catabolism from the rapid turnover pool. This 
catabolic assumption appears justified in humans (16). 
Only studies demonstrating satisfactory simulation of the 
experimental data and precise determinations (fractional 
standard deviation < 12%) of the three fractional rate 
constants were included in the data. Three studies of 
chow-fed homozygotes and two of controls were not in- 
cluded because one or more parameters were 
insufficiently precise. The homozygotes and control 
studies that were not included demonstrated the same 
respective properties as those presented. The mass of the 
injection compartment (pool 1 or R) was determined by 
the program from the fit of the data and the total mass in 
the body, and the cholesterol transport through the body 
was calculated from these data, using the three fractional 
rate constants obtained from the function. Body 
cholesterol transport was the product of the mass in the 
rapid pool (R) and the total body fractional catabolic rate, 
both of which were the best determined (FSD < 5 % )  of 
all the parameters. This value differs from plasma trans- 
port that was the product of the fractional plasma clear- 
ance rate and the vascular cholesterol pool. Plasma 
cholesterol transport was only quantitated in the mutant. 
Body cholesterol input indicates new cholesterol entering 
the body. Body cholesterol transport, as defined here, is 
that fraction of total transport destined for catabolism and 
was calculated as described above. In steady state condi- 
tions, input, body cholesterol transport, and cholesterol- 
derived compounds excreted are the same. Significance 
determinations were obtained with a two-tailed Student’s 
t test or by repeated measures of analysis of variance (18). 
RESULTS 
When normal animals were fed regular chow, the 
plasma decay of tracer cholesterol had a distinctly more 
rapid initial than terminal exponential (Fig. I). In the 
homozygous apoE-deficient mutants, on the other hand, 
the slopes of the initial and terminal exponential were 
similar, and the integral of the function was considerably 
larger than normal (Fig. 1). The compartmental analyses 
of these data, using a two-pool system with catabolism 
solely from the rapid pool (R) in equilibrium with a 
slower turning over pool (S), indicate that the total body 
TABLE 1 .  In vivo cholesterol transport in chow-fed normal and apoE-deficient homozygote mice 
Transport Fractional Transfer Rates Day-’ Pool Size pnol 
R+S S + R  FCR R Total pmollday p”/day/lO g 
+ / + ,  n = 6 0.95 i 0.05 0.55 f 0.07 0.51 + 0.06 (0.29-0.72) 17 i 3 48 f 5 (33-55) 8.5 i 0.9 2.9 i 0.7 
- I - ,  n = 5 0.29 + 0.01‘ 0.52 i 0.11 0.17 + 0.02* (0.12-0.20) 41 i 2‘ 68 i 5“(57-82) 6.9 f . 7  2.8 * 0.3 
Data represent the mean f SE of the number of studies indicated. The mean weight f SE of the mutants were 29 
Significantly different from control at “P < 0.05, *P < 0.01, ‘P < 0,001. 
3 and of controls 25 f 3 
g.  The values within parentheses are the ranges for these parameters. 
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TABLE 2. Tissue cholesterol mass in chow- and cholesterol-fed normal and apoE-deficient 
heterozygotes and homozygotes 
~~ 
Mass [ % Free] 
Chow-Fed Chol-Fed 










3.6 i 0.8(59) 
4.9 i 0.3(63) 
8.3 i 1.8(66) 
4.4 f 1.0(71) 
5.7 k 1.0(82) 
4.6 f 0.8(67) 
7.7 f 1.3(67) 
8.2 * 2.3(66) 
2.4 i 0.1(71) 
,umol/g (w/w) t SE 
3.3 i 0.5(69) 7.2 * 0.5(43) 
5.9 k 0.3(83) 8.2 f 1.5(69) 
6.4 k 0.3(64) * 6.9 i 0.8(69) 
2.8 i 0.8(54) 3.1 k 0.5(77) 
5.4 + 0.8(62) 3.9 f 0.5(81) 
6.2 i 0.8(62) 4.4 f 0.5(83) 
11.3 f 2.3(68) 8.0 k 0.8(66) 
5.9 k 1.5(65) 6.9 f 1.5(70) 
12.3 + 0.3(68)” 2.8 k 0.3(66) 
1.8 f 1.0(75) 
10.8 k 1.3(50)” 
9.5 f 0.5(56)b 
4.4 * 0.8(41) 
9.8 i 0.8(27)‘ 
9.5 f 0.5(41)’ 
16.2 i 1.8(62) 
13.4 f 1.8(52)“ 
27.8 k 2.1(62)* 
The data are the means of the number of mice indicated, assayed at the conclusion of the cholesterol turnover 
Significantly different from chow controls or respective chow homozygote at “P < 0.01 or ’f‘ < .001. 
‘The percent of free cholesterol is significantly less than respective control P < 0.05. 
study (Table 1). Data within parentheses are the percent free cholesterol. 
cholesterol fractional catabolic rate in the homozygotes is 
one-third of that in normal mice (Table 1). The fractional 
transfer from R to S is considerably slower for the 
homozygotes than for the normal mice. The fractional 
transfer from S to R, the size of S, and the cholesterol 
transport between pools in homozygotes fed chow are 
equivalent to that in normals. This indicates that the lack 
of apoE influences the effectiveness of cholesterol transfer 
from pool R to S but not out of S. 
Despite the smaller body cholesterol fractional cata- 
bolic rate, the total transport of cholesterol through the 
body of homozygotes fed chow is the same as normal. 
This is because the size of R is increased in homozygotes. 
While about two-thirds of body cholesterol in normal 
mice is in the slower turning over pool, the major portion 
of body cholesterol in homozygotes is in the rapid tur- 
nover pool. Total body cholesterol is significantly larger in 
the mutant and this cholesterol increment was confined to 
the rapid turnover pool. Plasma cholesterol is an ap- 
preciable component of this pool and the large difference 
in plasma cholesterol between mutants and control mice 
(Table 2) was estimated to account for at least half of the 
mutant increment in pool R and body cholesterol. The 
cholesterol contents and ratios between free cholesterol 
and cholesteryl ester in various tissues of chow-fed nor- 
mals and homozygotes are not significantly different (Ta- 
ble 2). As these mice were fed chow, with a cholesterol in- 
take of 0.01% of total food intake or 1.2 pmol of 
cholesterol (assuming total absorption), cholesterol input 
was more than 80% synthetic. This similarity in synthetic 
input in the mutants and normals suggests either that 
apoE-independent cholesterol entry into cells regulates 
synthesis as effectively as does apoE-dependent 
cholesterol uptake, or that cellular cholesterol synthesis is 
primarily regulated by other pathways (Le., B-100, etc.). 
Feeding a diet containing 1% cholesterol for a month 
prior to study considerably influenced the plasma decay 
of cholesterol in both normal and apoE-deficient mice 
(Fig. 2). In comparison to the chow diet, the tracer 
decayed more rapidly with cholesterol feeding, resulting 
in smaller integrals for the function. The body cholesterol 
fractional catabolic rate increased threefold for the con- 
trols and doubled for the apoE-deficient homozygotes in 
comparison to chow feeding (Table 3). Body cholesterol 
transport nearly tripled in both homozygotes and nor- 
mals. However, while the plasma cholesterol, R, and total 
+I+ 
. 
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Fig. 2. Plasma cholesterol decay in cholesterol-fed normal and apoE- 
deficient mice. The data are representative plasma cholesterol specific 
activity functions after the intravenous injection of [1,2-3H]cholesterol in 
normals (+/+,  top panel) and homozygotes (-I-, bottom panel) fed 1% 
cholesterol. 
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TABLE 3. In vivo cholesterol transport in cholesterol-fed normal and homozygote apE-deficient mice 
Fractional Transfer Rates Day-' Pool Size pmol Transport 
R+S S+R FCR R Total pmollday pmolldayll0 g 
+ / + ,  n = 6 1.56 f 0.4 0.43 i 0.1 1.58 f 0.15 (1.1-2.3) 12 f 1 59 i 1 1  (39-105) 19.9 f 3.4 8 . 4  f 1.3 
- / - ,  n = 4 1.70 f 0.4 0.92 f 0.2  0.33 f. 0.03" (0.26-0.43) 73 f 15* 166 f 21* (117-211) 22.5 f 3.0 10.8 f 1.0 
Control mice and apoE-deficient mutants were maintained on 1 % cholesterol, 10% lard diets for 4 weeks prior to study. Serum and tissue cholester- 
ol contents are described in Table 2. Data are means f SE of indicated mice number. Mean i SE weights of mutants were 21 * 28 and controls 
24 i 3*. The values within parentheses are in the ranges for these parameters. 
"Significantly different than control at P < 0.001. 
'Significantly different than control at P < 0.01. 
body cholesterol were substantially unchanged in the con- 
trols, each of these parameters increased considerably in 
homozygotes. Most of the cholesterol in chow-fed mutant 
mice was in R, but this changed with cholesterol feeding. 
The slow turnover pool of the homozygotes now contained 
the most cholesterol. The appreciable rise in both the 
body cholesterol fractional catabolic rate and cholesterol 
transport of the homozygotes in response to cholesterol 
feeding indicates that the cholesterol transport of these 
mice is not saturated and can be increased. However, this 
increase in cholesterol transport is achieved only with en- 
suing increases in plasma and body cholesterol. 
Cholesterol content in the liver of control animals dou- 
bled in response to a high cholesterol diet. This increase 
was primarily in hepatic cholesteryl ester. There was little 
change in other tissues of control mice. The opposite was 
true for the homozygous mutants. There was no change 
in the hepatic cholesterol content, particularly cholesteryl 
ester, while significant increases in peripheral tissue 
+/+ 
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Fig. 3. Plasma cholesterol decay in lovastatin treated normal (+/+) 
and apoE-deficient (-/-) mice. The data are representative plasma 
cholesterol specific activity functions after the intravenous injection of 
[1,2-3H]cholesterol in normals (top panel) and homozygotes (bottom 
panel) fed 0.025% lovastatin. 
cholesterol and a shift to cholesteryl ester were observed 
after a high cholesterol diet (Table 2). Studies stressing the 
system with dietary cholesterol emphasize the importance 
of apoE-dependent hepatic uptake in protecting plasma 
and peripheral tissues from elevations in plasma 
cholesterol concentrations when transport is increased. 
Lovastatin treatment of two homozygous mice resulted 
in a significant and paradoxical increase in plasma 
cholesterol concentration for both; 10.7 rt .5 and 
12.6 1.2 pmol/ml prior to and 18.7 * 1.6 and 20.9 * 1.7 
pmol/ml, respectively, during treatment (n = 5 for each, 
P < 0.001 and P < 0.01, respectively). No significant 
change was noted in the plasma cholesterol concentra- 
tions of control mice on lovastatin; 2.5 .1 prior to 
(n = 5) and 2.3 f .1 fimol/ml (n = 6) during treatment. 
Plasma tracer cholesterol decay in the homozygotes was 
more rapid on the lovastatin (Fig. 3) than on chow (Fig. 
1). Body cholesterol fractional catabolic rate almost tri- 
pled and body cholesterol transport doubled on treatment 
with the inhibitor of cholesterol synthesis (Table 4). Simi- 
lar to the expanded body cholesterol with cholesterol feed- 
ing, the increased transport of endogenous cholesterol 
also resulted in higher body cholesterol contents. Also 
analogous to cholesterol feeding, most of the mass incre- 
ment was found in the slow turnover pool. Control mice 
responded to lovastatin treatment with no change in 
plasma cholesterol, a modest increment in body 
cholesterol fractional catabolic rate, and decreased pool R 
and body cholesterol mass when compared to unsup- 
plemented chow. 
To evaluate the relevance of mutant plasma lipoprotein 
cholesterol transport to the observed changes in body 
cholesterol kinetics, cholesterol-labeled lipoproteins in the 
serum of mutants were injected into chow-fed controls 
and homozygotes. Homozygote plasma lipoprotein 
cholesterol clearance was considerably delayed in mutants 
compared to normals (Fig. 4). When these data were ana- 
lyzed in a one-compartment system, the fractional mutant 
lipoprotein cholesterol clearance rate was 0.6 * 0.02/h in 
normals and 0.07 * 0.004/h in homozygotes. For the 
homozygote this would result in a plasma cholesterol 
transport that was two to three times that of total body 
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TABLE 4. In vivo cholesterol transport in chow-fed, lovastatin-treated normal and 
homozygote apoE-deficient mice 
Fractional Transfer Rates Day-' Pool Size pmol 
R+S S-R FCR R Total Transport pmollday 
+ / + , n = 2  0 . 9 1 i O . 0 2  0 . 3 1 t 0 . 0 4  0 . 7 7 + 0 . 0 4  9 + 1  3 2 t 4  6.8 t 0.9 
- / - ,  n = 2 0.42 i 0.04 0.31 + 0.04 0.47 0.04 35 t 2 87 + 12 16.5 t 0.8 
Control mice (mean f SD wt 23.5 f 2 g, n = 2) and homozygous apoE-deficient (mean wt 26.6 t 3.0 g, n = 2) 
were fed 0.025% lovastatin in standard rodent chow for 4 weeks prior to study. Data are the means t SD of dupli- 
cates of mutants and controls. 
catabolic transport. Similar estimates cannot be made for 
the normals because total plasma cholesterol transport 
was not measured. Transfer of mutant lipoprotein 
cholesterol to other pools, Le., high density plasma 
lipoproteins and biliary sterols, was much less for 
homozygotes than normals (Fig. 5). Normals demon- 
strated return of injected cholesterol to plasma high den- 
sity lipoproteins, mainly as free cholesterol (Fig. 5A). 
This was similar to that observed for rat chylomicron 
cholesterol (19) and occurred at a time described (20) for 
hepatic chylomicron cholesteryl ester hydrolysis. 
h 
Fig. 4. Lower density plasma lipoprotein cholesterol tracer decay. The 
data are the mean i SE d < 1.063 g/ml lipoprotein cholesterol specific 
activities of four homozygotes (top panel) and three normals (lower 
panel) after the injection of homozygote cholesterol-labeled lipoproteins 
(> 65% cholesteryl ester). 
Sequential specific activities in bile acids of normal and 
homozygous mice were significantly different after injec- 
tions of mutant lipoproteins (Fig. 5B). Specific activity in 
homozygotes was one-fifth the normal and did not 
demonstrate the progressive increase as did controls. The 
bile acid pool sizes obtained from the dilution of 
[14C]taurocholate were 6.0 * 1.5 pmoles (n = 5) for nor- 
mals and 3.5 * 0.03 pmoles (n = 6) for homozygotes. 
The lower specific activities of the mutant bile acids could 
not be explained by considerably larger bile acid pools 
with dilution in the mutant. Biliary neutral sterol specific 
activities were also about five-fold greater for normals 
than homozygotes (Fig. 5C). For both types of mice, the 
neutral sterol specific activities were considerably higher 
than the bile acid after receiving the cholesterol-labeled 
lipoproteins from the mutants. 
DISCUSSION 
The absence of apoE results in a considerable increase 
of plasma cholesterol in both humans (21) and mice (6). 
Plasma lipoproteins accumulating in such mutations have 
physical characteristics and increased apoB-48 content 
similar to chylomicron and very low density lipoprotein 
remnants. These lipoproteins would be anticipated (1) to 
be poorly cleared without apoE. They differ, however, 
from the remnants of hepatectomized rats (22) and hu-  
mans with Type I11 (23), having appreciably less triglycer- 
ide than either. Possibly, apoE-independent lipoprotein 
transport results in longer plasma residence times with 
greater exposures to lipase activity. 
Impaired body cholesterol catabolism is consistently 
observed in homozygotes with apoE-independent plasma 
lipoprotein transport. Compared with controls, this defect 
is characterized by lower body cholesterol fractional cata- 
bolic rates and an increased body cholesterol mass for 
each mutant evaluated. The mice were studied during 
differing rates of transport and with differing sources of 
cholesterol entering the body. Irrespective of these condi- 
tions, the mutants always had a consistently larger body 
cholesterol mass, a greater distribution of this mass in the 
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produced by this agent had not occurred in these mutants 
or that apoE-independent plasma clearance was not 
mediated by this receptor. These issues are under study. 
Lovastatin and cholesterol feeding enhanced en- 
dogenous and exogenous body cholesterol transport, 
respectively, in the apoE-deficient mutant. The large ex- 
pansion of plasma and body cholesterol needed during 
chow feeding to produce mutant transports similar to nor- 
mals could suggest that this was maximum transport in a 
saturated system. The results with lovastatin and 
cholesterol supplementation demonstrate considerable ca- 
pacity to transport body cholesterol from synthetic and 
exogenous sources. The enhanced body cholesterol trans- 
port during cholesterol feeding resulted not only from an 
increase in the catabolic (R) pool size, but a doubling of 
the body cholesterol fractional catabolic rate as compared 
to chow. Lovastatin treatment produced a tripling of frac- 
tional catabolic rate in the mutant with little change in R. 
The enhanced catabolic efficiency (Le., fractional cata- 
bolic rate) demonstrated by mutants when stimulated to 
transport more cholesterol possibly relates to changes ob- 
served in plasma lipoproteins. If plasma lipoprotein 
cholesterol access to liver importantly influences body 
cholesterol FCR, the higher concentrations of these 
lipoproteins during cholesterol or lovastatin feeding 
should facilitate greater cellular access by a low affinity 
transport system. Secondly, a potential shift in size to 
larger lipoproteins should result in greater cholesterol en- 
try into cells with each lipoprotein particle. This adaptive 
catabolic response by the mutants is under investigation. 
Cholesterol feeding increased body cholesterol trans- 
port to a similar extent in both controls and homozygotes 
indicating that intestinal cholesterol absorption was not 
attenuated in the absence of apoE. The normal mouse 
responds to this enhanced body cholesterol transport with 
a modest hepatic cholesterol increase and no change in 
other tissues including plasma. In the absence of apoE, 
this is reversed so that the liver revealed little change in 
cholesterol, while peripheral tissues, particularly plasma, 
demonstrated considerable increments. These data and 
those from lovastatin feeding demonstrate the importance 
of the high affinity apoE-mediated hepatic lipoprotein ac- 
cess pathway in the maintenance of normal plasma and 
peripheral tissue cholesterol concentrations when trans- 
port is increased. In the normal mouse, an increase in 
hepatic rather than plasma cholesterol occurs, with 
greater transport indicating that apoE-mediated plasma 
lipoprotein access to liver saturates later than other 
hepatic cholesterol transfer processes. In the homozygote, 
where hepatic access appears to be a limiting step in body 
cholesterol transport, a much more impressive increase in 
plasma concentration occurs. The appreciable cholesterol 
accumulation in peripheral tissues quite likely results 
from this plasma increment. High affinity apoE-mediated 
cholesterol transfer does not require increased plasma 
concentrations to increase body cholesterol transport. 
The subsequent peripheral tissue increments and their 
pathologic consequences are avoided. 
. The absence of apoE in mice results in an increment of 
plasma lipoprotein cholesterol concentration. This 
cholesterol was primarily in lower density, remnant-like 
lipoproteins, rather than the high density lipoproteins of 
normals. This mutant plasma lipoprotein cholesterol 
increment resulted from defective plasma clearance in the 
chow-fed mouse and comprised at least half of the in- 
crease in total body cholesterol observed. This rise in 
body cholesterol mass and the appreciably lower body 
cholesterol fractional catabolic rate clearly demonstrate 
an abnormality of body cholesterol catabolism in the 
apoE-deficient mutant. It is possible that the plasma 
lipoprotein clearance defect is the primary, and even the 
sole, cause of this catabolic abnormality but at present 
this is uncertain. Despite the abnormal catabolism, the 
mutant was able to transport at least as much cholesterol 
as controls in each of the three metabolic conditions 
studied. Cholesterol transport capacity in mutants via the 
apoE-independent low affinity system was equivalent to 
normals, but always at considerable expansions of plasma 
and body cholesterol mass. &E 
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